Further, we demonstrated that at higher concentrations, BCI-121 was significantly cytotoxic to primary MB tumor samples with high Myc expression ex vivo and that SMYD3 knockdown significantly reduced Myc expression in vitro, further supporting the clinical benefits of targeting SMYD3 in Group 3 Myc+ MB patients. The gene discussed is SMYD3; the disease is neoplasm.